Ardea To Present Data On HIV Non Nucleoside Reverse Transcriptase Inhibitor And Two MEK Inhibitors At Upcoming Medical Conferences
January 30th, 2008 by 
Barry - Admin BioPharmArena
Ardea Biosciences, Inc. (Nasdaq: RDEA) announced that data will be presented on its second generation non-nucleoside reverse transcriptase inhibitors (NNRTIs), at the 21st International Conference on Antiviral Research (ICAR). Additionally, data on two of the Company’s mitogen-activated ERK kinase (MEK) inhibitors, RDEA119 and RDEA436, will be presented at the American Association for Cancer Research (AACR) annual meeting.
The presentation details are as follows:
– 21st ICAR in Montreal, Quebec, Canada
Date/Time: Monday, April 14, 2008 at 4:00 p.m. Eastern Time
Title: A Novel NNRTI Class with Potent Anti-HIV Activity against
NNRTI-Resistant Viruses
Location: Poster Session 1 (Poster #80)
- AACR Annual Meeting in San Diego, California
Date/Time: Tuesday, April 15, 2008 at 1:00 p.m. Pacific Time
Title: RDEA119, a Potent and Highly Specific MEK Inhibitor is
Efficacious in Mouse Tumor Xenograft Studies
Location: Poster Session 32 (Poster #4878), Exhibit Hall B-F
Date/Time: Tuesday, April 15, 2008 at 1:00 p.m. Pacific Time
Title: RDEA436, a Novel MEK Inhibitor with Favorable
Pharmacokinetic Properties
Location: Poster Session 32 (Poster #4895), Exhibit Hall B-F
Posted in News, Research and Development, Clinical Research and Clincal Trials | 